La Plata, marzo 2023

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_CURRICULUM VITAE**

**a) Datos Personales**

Apellido: **Rozenfeld**

Nombres: **Paula Adriana**

D.N.I.: 23569991

Domicilio laboral: IIFP. Boulevard 120 y 62. (1900) La Plata

Fecha de nacimiento: 4 de enero de 1974

E-mail: paurlarozenfeld@gmail.com

**b) Títulos obtenidos**

Denominación: **Bioquímica**

Institución que lo expidió: Facultad de Ciencias Exactas- Universidad Nacional de La Plata (UNLP).

Fecha de ingreso: 1992. Fecha de obtención: 18 de febrero de 1998

Promedio con y sin aplazos: 9,29

Denominación: **Doctora de la Facultad de Ciencias Exactas**

Institución que lo expidió: Facultad de Ciencias Exactas- Universidad Nacional de La Plata (UNLP).

Fecha de obtención: 25 de abril de 2003

Calificación: Sobresaliente (10)

**c) Posición Actual**

-**Investigador Principal** de la Carrera de Investigador Científico de CONICET.

Lugar de trabajo: IIFP (Fac Cs Exactas, UNLP-CONICET)

**-Responsable de DIEL**: Laboratorio de Diagnóstico de Enfermedades de Almacenamiento Lisosomal. IIFP (Instituto de Estudios Inmunológicos y Fisiopatológicos), Facultad de Ciencias Exactas, UNLP y CONICET

**d) Publicaciones científicas**

d-i) en revistas científicas (con referato)

1 Polyphenoloxidase activity from Selva strawberry fruit (*Fragaria x ananassa,* Duch.): characterisation and partial purification. Serradell, M.A.; Rozenfeld, P.A.; Martinez, G.A.; Civello, P.M.; Chaves, A.R.; Añón, M.C. Journal of the Science of Food and Agriculture 2000. 80 (9): 1421-1427.**ISSN** '**1097-0010**

2 Evaluation of the residual antigenicity and allergenicity of cow's milk substitutes by in vitro tests. Docena, G; Rozenfeld, P; Fernández, R; Fossati, CA. Allergy 2002, 57 (2): 83-91.**PrintISSN:** 0105-4538 **Online ISSN:** 1398-9995

3 Detection and identification of a soy protein component that cross react with caseins from cow milk. Rozenfeld, P; Docena, G; Añón, MC; Fossati, CA. Clinical and Experimental Immunology 2002, 130: 49-58. ISSN: 0009-9104

4 A successful approach for the detection of Fabry patients in Argentina. Paula A Rozenfeld\* PhD, Analía Tarabuso† MD, Roberto Ebner ‡ MD, German Ramallo MD §, Carlos A Fossati\* PhD. Clinical Genetics 2006, 69: 344-348. **Print ISSN:** 0009-9163**Online ISSN:** 1399-0004

5 Immunofluorescence detection of Gb3 deposits in conjunctival biopsies of hemizygote and heterozygote patients with Fabry´s disease. Rozenfeld PA, Croxatto O, Ebner R, Fossati CA. Clinical and Experimental Ophtalmology, 2006, 34: 689-694. Print ISSN:1442-6404, Online: 1442-9071.

6 High incidence of autoantibodies in Fabry disease patients. P. Martinez, M. Aggio, P. Rozenfeld. Journal of Inherited Metabolic Diseases, 2007, 24: 365-369. ISSN: 0141-8955 (Print) 1573-2665 (Online)

7 Manifestaciones nefrológicas de pacientes con Enfermedad de Fabry en Argentina.

Neumann Pablo, Rozenfeld Paula. Nefrologia, Trasplante e Hipertensión 2007, 27: 99-102. ISSN: 0326-3428

8 An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring. Paula A Rozenfeld#; Nicolas P De Francesco#, Gustavo JC Borrajo\*, Romina Ceci#, Carlos A Fossati#. Clin Chim Acta 2009, 403: 194-197. ISSN: 0009-8981

9 Leukocyte perturbation associated with Fabry disease. P Rozenfeld1, E Agriello2, N De Francesco1, P Martinez2, C Fossati1. Journal of Inherited Metabolic Diseases 2009 ISSN: 0141-8955 (Print) 1573-2665 (Online)

10 "Fabry disease: Treatment and diagnosis". Rozenfeld P. IUBMB Life 2009, 61: 1043 – 1050. ISSN 1521-6543 print/ISSN 1521-6551 online

11 Evaluación de pacientes con enfermedad de Fabry en la Argentina. AADELFA. Medicina (Buenos Aires) 2010; 70: 37-43. ISSN 0025-7680

Reisin R, Doxastaquis G, Kisinovsky I, Caceres G, Tarabuso A, Neumann P, Ebner R, Martinez P, Rozenfeld PA.

12 Myocardial alterations in the murine model of Fabry disease can be reversed by enzyme replacement therapy (ERT). Paula A. Rozenfeld, Mariana Fritz, Paula Blanco, Pedro Gonzalez, Gustavo J. Rinaldi. Canadian J Cardiology 2011 (in press).

13 Treatment of Fabry disease: Current and emerging strategies Dr Paula Rozenfeld1, PhD, Dr Pablo M Neumann2, MD. Current Pharm Biotechnol 2011 (in press)

14 Guía argentina para el diagnóstico, el seguimiento y el tratamiento de la Mucopolisacaridosis Tipo II (MPS-II) o Enfermedad de Hunter, Guelbert N, Amartino H, Arberas C, Azar N, Bay L, Fainboim A, Fernández MC, Giner A, Ilari R, Marchione D, Masllorens F, Perochena J, Riccheri C, Richard L, Rozenfeld P, Serafin E, Szlago M, Valdez R. Archivos Argentinos de Pediatria 2011, 109: 175-181.

15 Higher apoptotic state in Fabry disease peripheral blood mononuclear cells. Effect of globotriaosylceramide. Pablo N de Francesco, Bioc; Juan M Mucci, Lic; Romina Ceci, Bioc; Carlos A Fossati, PhD. Mol Genet Metab 2011, 104: 319-324.

16 Reliability of enzyme assays in dried blood spots for diagnosis of 4 lysosomal storage disorders. Romina Ceci, Pablo N de Francesco, Juan Mucci, Lorena N. Cancelarich, Carlos A Fossati, Paula A Rozenfeld. Advances in Biological Chemistry, 2011, 1, 58-64 (ISSN Print: 2162-2183 ISSN Online: 2162-2191

17 Induction of osteoclastogenesis in an *in vitro* model of Gaucher disease is mediated by T cells via TNF-α. Juan M Mucci1, Romina Scian2, Pablo N De Francesco1, Florencia Suquelli García1, Romina Ceci1, Carlos A Fossati, M. Victoria Delpino2, Paula A Rozenfeld1. GENE, 2012, 509: 51-59

18 Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Pablo N De Francesco; Juan M Mucci; Romina Ceci; Carlos A Fossati; Rozenfeld PA. Mol Genet Metab 2013, 109: 93-99

19 Two-dimensional speckle tracking echocardiography for early detection of myocardial damage in young patients with Fabry disease. Echocardiography 2013, 30(9):1069-1077. [Saccheri MC](http://www.ncbi.nlm.nih.gov/pubmed?term=Saccheri%20MC%5BAuthor%5D&cauthor=true&cauthor_uid=23600802), [Cianciulli TF](http://www.ncbi.nlm.nih.gov/pubmed?term=Cianciulli%20TF%5BAuthor%5D&cauthor=true&cauthor_uid=23600802), [Lax JA](http://www.ncbi.nlm.nih.gov/pubmed?term=Lax%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=23600802), [Gagliardi JA](http://www.ncbi.nlm.nih.gov/pubmed?term=Gagliardi%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=23600802), [Cáceres GL](http://www.ncbi.nlm.nih.gov/pubmed?term=C%C3%A1ceres%20GL%5BAuthor%5D&cauthor=true&cauthor_uid=23600802), [Quarin AE](http://www.ncbi.nlm.nih.gov/pubmed?term=Quarin%20AE%5BAuthor%5D&cauthor=true&cauthor_uid=23600802), [Kisinovsky I](http://www.ncbi.nlm.nih.gov/pubmed?term=Kisinovsky%20I%5BAuthor%5D&cauthor=true&cauthor_uid=23600802), [Rozenfeld PA](http://www.ncbi.nlm.nih.gov/pubmed?term=Rozenfeld%20PA%5BAuthor%5D&cauthor=true&cauthor_uid=23600802), [Reisin RC](http://www.ncbi.nlm.nih.gov/pubmed?term=Reisin%20RC%5BAuthor%5D&cauthor=true&cauthor_uid=23600802); [AADELFA](http://www.ncbi.nlm.nih.gov/pubmed?term=AADELFA%5BCorporate%20Author%5D).

20 Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease. Juan M Mucci1, Florencia Suqueli García1,Pablo N de Francesco1, Romina Ceci1, Di Genaro S2, Carlos A Fossati1, M. Victoria Delpino3, Paula A Rozenfeld1. Gene 2013, 532: 186-191 ISSN: 0378-1119

21 Guidelines for diagnosis, monitoring and treatment of Fabry disease. [Grupo Argentino de Diagnóstico y Tratamiento de la enfermedad de Fabry](http://www.ncbi.nlm.nih.gov/pubmed?term=Grupo%20Argentino%20de%20Diagn%C3%B3stico%20y%20Tratamiento%20de%20la%20enfermedad%20de%20Fabry%5BCorporate%20Author%5D) ([Consenso de Médicos de AADELFA y GADYTEF](http://www.ncbi.nlm.nih.gov/pubmed?term=Consenso%20de%20M%C3%A9dicos%20de%20AADELFA%20y%20GADYTEF%5BCorporate%20Author%5D)). [Neumann P](http://www.ncbi.nlm.nih.gov/pubmed?term=Neumann%20P%5BAuthor%5D&cauthor=true&cauthor_uid=24152410),[Antongiovanni N](http://www.ncbi.nlm.nih.gov/pubmed?term=Antongiovanni%20N%5BAuthor%5D&cauthor=true&cauthor_uid=24152410),[Fainboim A](http://www.ncbi.nlm.nih.gov/pubmed?term=Fainboim%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24152410),[Kisinovsky I](http://www.ncbi.nlm.nih.gov/pubmed?term=Kisinovsky%20I%5BAuthor%5D&cauthor=true&cauthor_uid=24152410). [Collaborators (23)](http://www.ncbi.nlm.nih.gov/pubmed/24152410) [Amartino H](http://www.ncbi.nlm.nih.gov/pubmed?term=Amartino%20H),[Cabrera G](http://www.ncbi.nlm.nih.gov/pubmed?term=Cabrera%20G),[Carmona S](http://www.ncbi.nlm.nih.gov/pubmed?term=Carmona%20S),[Ceci R](http://www.ncbi.nlm.nih.gov/pubmed?term=Ceci%20R),[Cicerán A](http://www.ncbi.nlm.nih.gov/pubmed?term=Cicer%C3%A1n%20A),[Choua M](http://www.ncbi.nlm.nih.gov/pubmed?term=Choua%20M),[Doxastakis G](http://www.ncbi.nlm.nih.gov/pubmed?term=Doxastakis%20G),[De Maio S](http://www.ncbi.nlm.nih.gov/pubmed?term=De%20Maio%20S),[Ebner R](http://www.ncbi.nlm.nih.gov/pubmed?term=Ebner%20R),[Escobar AM](http://www.ncbi.nlm.nih.gov/pubmed?term=Escobar%20AM),[Ferrari G](http://www.ncbi.nlm.nih.gov/pubmed?term=Ferrari%20G),[Forrester M](http://www.ncbi.nlm.nih.gov/pubmed?term=Forrester%20M),[Guelbert N](http://www.ncbi.nlm.nih.gov/pubmed?term=Guelbert%20N),[Luna P](http://www.ncbi.nlm.nih.gov/pubmed?term=Luna%20P),[Marchesoni C](http://www.ncbi.nlm.nih.gov/pubmed?term=Marchesoni%20C),[Masllorens F](http://www.ncbi.nlm.nih.gov/pubmed?term=Masllorens%20F),[Politei J](http://www.ncbi.nlm.nih.gov/pubmed?term=Politei%20J),[Reisin R](http://www.ncbi.nlm.nih.gov/pubmed?term=Reisin%20R),[Ripeau D](http://www.ncbi.nlm.nih.gov/pubmed?term=Ripeau%20D),[Rozenfeld P](http://www.ncbi.nlm.nih.gov/pubmed?term=Rozenfeld%20P),[Serebrinsky G](http://www.ncbi.nlm.nih.gov/pubmed?term=Serebrinsky%20G),[Tarabuso AL](http://www.ncbi.nlm.nih.gov/pubmed?term=Tarabuso%20AL),[Trípoli J](http://www.ncbi.nlm.nih.gov/pubmed?term=Tr%C3%ADpoli%20J). [Medicina (B Aires).](http://www.ncbi.nlm.nih.gov/pubmed/24152410) 2013;73(5):482-494. ISSN 0025-7680

22 Examining the impact of bone pathology on type I Gaucher's disease. Mucci JM, Rozenfeld PA. Clinical Lipidology 2014, 9: 61-70. (1746-0875)

23 Identification of 17 novel mutations in 40 Argentinean unrelated families with mucopolysaccharidosis type II (Hunter syndrome). Amartino Ha; Ceci Rb; Masllorens Fc; Gal Ad; Arberas C e; Bay Lf; Ilari Rg; Dipierri Jh; Specola Ni; Cabrera A (12) j; Rozenfeld P (2). MGM Reports 2014, 401-406ISSN: 2214-4269

24 Pathogenesis of Bone Alterations in Gaucher disease: The Role of Immune System. Mucci Juan Marcos, Rozenfeld Paula. J Imm Res 2015, Article ID 192761, http://dx.doi.org/10.1155/2015/192761. Invited review.

25 Apical Left Ventricular Hypertrophy and Mid-Ventricular Obstruction in Fabry Disease. Tomas F. Cianciulli, Marıa C. Saccheri, Segundo Fernandez, Cinthia Fernandez, Paula A. Rozenfeld, Isaac Kisinovsky, and AADELFA. Ecocardiography 2015 ;32(5):860-863.

26 “Proinflammatory and proosteoclastogenic potential of peripheral blood mononuclear cells from Gaucher patients: implication for bone pathology”. Mucci JM1, Cuello MF2, Kisinovsky I3, Larroude M4, Delpino MV5; Rozenfeld PA. BCMD 2015, 55: 134-143 (ISSN:1079-9796)

27 The continuous challenge of diagnose Fabry patients in Argentina: genotype, experiences, anecdotes and new learnings. Paula A Rozenfeld1, Romina Ceci1, Norma Roa1, Isaac Kisinovsky2 JIEMS 2015 1-7. Print ISSN: 2326-4098

28 Enfermedad de Fabry en Argentina. Rozenfeld PA. Acta Bioquimica Clinica Latinoamericana 2016, 50(1): 17-25. ISSN: 0325-2957

29 Osteocyte Alterations Induce Osteoclastogenesis in an in Vitro Model of Gaucher Disease. Constanza Bondar\*1, Maximiliano Ormazabal\*1, Andrea Crivaro1, Malena Ferreyra-Compagnucci1, María Victoria Delpino2, Paula Adriana Rozenfeld#1, Juan Marcos Mucci. International Journal of Molecular Sciences 2017, 18: 112. **ISSN** 1422-0067

30 Enfermedad hepática y dislipemia como manifestación de deficiencia de lipasa ácida lisosomal (LAL-D), aspectos clínicos, diagnósticos y nuevo tratamiento. Luisa Bay 1, Cristina Cañero Velasco 2, Mirta Ciocca 3, Andrea Cotti 4, Miriam Cuarterolo 5, Alejandro Fainboim6, Eduardo Fassio 7, Marcela Galoppo8, Federico Piñero9, Paula Rozenfeld10. Archivos Argentinos de Pediatria 2017, 115: 287 -293

31 In vitro osteoclastogenesis from Gaucher patients´cells correlates with bone mineral density but not with Chitotriosidase. Bondar C1, Mucci J1, Crivaro A1, Ormazabal M1, Ceci R1, Oliveri B2, González D3, Rozenfeld P1 \* Bone 2017, 103: 262-269 ISSN: 8756-3282

32 Contribution of inflammatory pathways to Fabry disease pathogenesis. Rozenfeld P, Feriozzi S. Molecular Genetics and Metabolism 2017, 122: 19-27. ISSN: 1096-7192

33 Prevalence of Fabry Disease in Young Patients with Stroke in Argentina. [Reisin RC](https://www.ncbi.nlm.nih.gov/pubmed/?term=Reisin%20RC%5BAuthor%5D&cauthor=true&cauthor_uid=29132836)1, [Mazziotti J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mazziotti%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29132836) ,[Cejas LL](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cejas%20LL%5BAuthor%5D&cauthor=true&cauthor_uid=29132836), [Zinnerman A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zinnerman%20A%5BAuthor%5D&cauthor=true&cauthor_uid=29132836), [Bonardo P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bonardo%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29132836)2, [Pardal MF](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pardal%20MF%5BAuthor%5D&cauthor=true&cauthor_uid=29132836), [Martínez A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mart%C3%ADnez%20A%5BAuthor%5D&cauthor=true&cauthor_uid=29132836), [Riccio P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Riccio%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29132836)4, [Ameriso S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ameriso%20S%5BAuthor%5D&cauthor=true&cauthor_uid=29132836), [Bendersky E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bendersky%20E%5BAuthor%5D&cauthor=true&cauthor_uid=29132836), [Nofal P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Nofal%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29132836)7, [Cairola P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cairola%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29132836)8, [Jure L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jure%20L%5BAuthor%5D&cauthor=true&cauthor_uid=29132836)9, [Sotelo A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sotelo%20A%5BAuthor%5D&cauthor=true&cauthor_uid=29132836)10, [Rozenfeld P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Rozenfeld%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29132836)11, [Ceci R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ceci%20R%5BAuthor%5D&cauthor=true&cauthor_uid=29132836)11, [Casas-Parera I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Casas-Parera%20I%5BAuthor%5D&cauthor=true&cauthor_uid=29132836)12, [Luceros AS](https://www.ncbi.nlm.nih.gov/pubmed/?term=Luceros%20AS%5BAuthor%5D&cauthor=true&cauthor_uid=29132836)13; [AISYF Investigators](https://www.ncbi.nlm.nih.gov/pubmed/?term=AISYF%20Investigators%5BCorporate%20Author%5D). [J Stroke Cerebrovasc Dis.](https://www.ncbi.nlm.nih.gov/pubmed/29132836) 2018, 27: 575-582. doi: 10.1016/j.jstrokecerebrovasdis.2017.09.045. 1052-3057

34 A Comprehensive Study of Bone Manifestations in Adult Gaucher Disease Type 1 Patients in Argentina Beatriz Oliveri1  · Diana González2  · Felisa Quiroga3  · Claudio Silva3  · Paula Rozenfeld. Calcified Tissue International (in press)

35 Efficacy of [Pentosan Polysulfate](https://www.ncbi.nlm.nih.gov/pubmed/29654542) in *in vitro* models of lysosomal storage disorders: Fabry and Gaucher Disease. Andrea N Crivaro1&, Juan M Mucci1&, Constanza M Bondar1, Maximiliano E Ormazabal1, Romina Ceci1, Calogera Simonaro2, Paula A Rozenfeld1\*. Plos One 2019, 14(5): e0217780. <https://doi>. org/10.1371/journal.pone.0217780)

36 Fabry pedigree analysis: a successful program for targeted genetic approach. Paula A Rozenfeld P1, Francisca M Masllorens2, Norma Roa3, Fernanda Rodriguez3, Mariela Bonnano4, Carolina Yvorra4, Romina Ceci1. Molecular Genetics & Genomic Medicine 2019 DOI: 10.1002/mgg3.794 Impact factor:2.695 - ISI Journal Citation Reports © Ranking: 2017:85/171 (GENETICS & HEREDITY).

37 Pathogenesis of Fabry nephropathy: the pathways leading to fibrosis. Paula Adriana Rozenfelda\*, María de los Angeles Bolla b, Pedro Quietoc, Pisani Ad, Feriozzi Se, Neuman Pf, Constanza Bondar. Molecular Genetics Metabolism 2020, 129: 132-141 Impact Factor: 3.610 . SCImago Journal Rank (SJR): 1.469. ISSN: 1096-7192.

38 CRISPR/Cas9 editing for Gaucher disease modelling. Eleonora Pavan1, Maximiliano Ormazabal1,2, Paolo Peruzzo1, Emilio Vaena2, Paula Rozenfeld2 and Andrea Dardis1,\*. IJMS, 2020, 21: 3268. doi:10.3390/ijms21093268, ISSN 1422-0067

39 Diagnóstico temprano de enfermedad de Gaucher mediante detección de manifestaciones óseas. BEATRIZ OLIVERI1, DIANA C. GONZÁLEZ2, PAULA ROZENFELD3,EMMA FERRARI4, GLADYS GUTIÉRREZ. Medicina, in press issn: 1669-9106

40 Gaucher disease-associated alterations in mesenchymal stem cells reduce osteogenesis and favour adipogenesis processes with concomitant increased osteoclastogenesis.  Crivaro A1, Bondar C1, Mucci JM1, Ormazabal M1, Feldman RA2, Delpino MV3, Rozenfeld PA. Molecular Genetics Metabolism 2020, 130: 274-282. <https://doi.org/10.1016/j.ymgme.2020.06.003>. ISSN: 1096-7192

41 Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative. Derralynn A. Hughes,1,2 Patricio Aguiar,3,4 Patrick B Deegan,5,6 Fatih Ezgü,7 Andrea Frustaci,8 Olivier Lidove,9 Aleš Linhart,10 Jean-Claude Lubanda,10 James C Moon,11 Kathleen Nicholls,12,13 Dau-Ming Niu,14,15 Albina Nowak,16,17 Uma Ramaswami,1 Ricardo Reisin,18 Paula Rozenfeld,19 Raphael Schiffmann,20 Einar Svarstad,21,22 Mark Thomas,23 Roser Torra,24 Bojan Vujkovac,25 David G Warnock,26 Michael L West,27 Jack Johnson,28,29 Mark Rolfe,30 Sandro Feriozzi.31 BMJ Open 2020;10:e035182. 2044-6055

42 Unraveling the mystery of Gaucher bone density pathophysiology. Rozenfeld PA1\*#, Crivaro AN1#, Ormazabal M1, Mucci JM1, Bondar C1, Delpino MV. Molecular Genetics Metabolism 2021: 132: 76-85

43 Upregulation of ASIC1a channels in an *in vitro* model of Fabry disease. Libia Catalina Salinas Castellanosa, Paula Rozenfeldb, Rodolfo Gabriel Gattoc, Ricardo Reisind, Osvaldo Daniel Uchitela,Carina Weissmann. Neurochemistry International 2020, 140: 104824 doi: 10.1016/j.neuint.2020.104824. issn: 0197-0186

44 FABRY DISEASE: INCREASED RISK OF STROKE IN THE COVID-19 ERA. Authors: Reisin Ricardo (MD),1,2 Rozenfeld Paula, 2,3 Bonardo Pablo (MD). Medycal Hypotheses 2020, 144: 110282. Impact factor: 1.375. Q3

Issn: 0306-9877

45 Standardising clinical outcomes measures for adult clinical trials in Fabry Disease: A global Delphi Consensus. D. Moreno-Martinez1, P. Aguiar2,C. Auray-Blais3 M. Beck4, D. G Bichet5, A. Burlina6, D. Cole7 , P. Elliott8 , U. Feldt-Rasmussen9, S. Feriozzi10, J. Fletcher11, R. Giugliani12, A. Jovanovic13, C. Kappmann14, M. Langeveld15, O. Lidove16, A. Linhart17, M. Mauer18, J. C Moon19, A. Muir20, A. Nowak21, J.P. Oliveira22, A. Ortiz23, G. Pintos-Morell24, J. Politei25, P. Rozenfeld26, R. Schiffmann27, E. Svarstad28,A. S Talbot29, M. Thomas30, C. Tøndell31, D. Warnock32, M. L West33, D. A Hughes1\*. MGM 2021, in press

46 New mutation in Fabry disease: c.448delG, first phenotypic description. .[EstebanCalabresea](https://www.sciencedirect.com/science/article/pii/S2214426921000021#!), [Guillermo Rodriguez Botta,bc](https://www.sciencedirect.com/science/article/pii/S2214426921000021#!)[Dra PaulaRosenfeld](https://www.sciencedirect.com/science/article/pii/S2214426921000021%22%20%5Cl%20%22%21)[d](https://www.sciencedirect.com/science/article/pii/S2214426921000021%22%20%5Cl%20%22%21). MGMreports 2021, 7:100708. ISSN: 2214-4269

47 Pathology and pathogenic pathways in Fabry nephropathy. Clinical and Experimental Nephrology 2021, <https://doi.org/10.1007/s10157-021-02058-z>. (IF=1,854) eISSN=1437-7799/pISSN=1342-1751

48 Major cardiovascular adverse events in Fabry disease patients receiving agalsidase alfa. [Gustavo Ferrari](https://pubmed.ncbi.nlm.nih.gov/?term=Ferrari+G&cauthor_id=33906135)[1](https://pubmed.ncbi.nlm.nih.gov/33906135/#affiliation-1), [Ricardo Reisin](https://pubmed.ncbi.nlm.nih.gov/?term=Reisin+R&cauthor_id=33906135)[2](https://pubmed.ncbi.nlm.nih.gov/33906135/#affiliation-2), [Isaac Kisinovsky](https://pubmed.ncbi.nlm.nih.gov/?term=Kisinovsky+I&cauthor_id=33906135)[3](https://pubmed.ncbi.nlm.nih.gov/33906135/#affiliation-3), [Pablo Neumann](https://pubmed.ncbi.nlm.nih.gov/?term=Neumann+P&cauthor_id=33906135)[4](https://pubmed.ncbi.nlm.nih.gov/33906135/#affiliation-4), [Laura Dragonetti](https://pubmed.ncbi.nlm.nih.gov/?term=Dragonetti+L&cauthor_id=33906135)[5](https://pubmed.ncbi.nlm.nih.gov/33906135/#affiliation-5), [Guillermo Cáceres](https://pubmed.ncbi.nlm.nih.gov/?term=C%C3%A1ceres+G&cauthor_id=33906135)[6](https://pubmed.ncbi.nlm.nih.gov/33906135/#affiliation-6), [Martin Choua](https://pubmed.ncbi.nlm.nih.gov/?term=Choua+M&cauthor_id=33906135)[7](https://pubmed.ncbi.nlm.nih.gov/33906135/#affiliation-7), [Paula Rozenfeld](https://pubmed.ncbi.nlm.nih.gov/?term=Rozenfeld+P&cauthor_id=33906135)[8](https://pubmed.ncbi.nlm.nih.gov/33906135/#affiliation-8), [Cintia Marchesoni](https://pubmed.ncbi.nlm.nih.gov/?term=Marchesoni+C&cauthor_id=33906135)[2](https://pubmed.ncbi.nlm.nih.gov/33906135/#affiliation-2), [Verónica Finn](https://pubmed.ncbi.nlm.nih.gov/?term=Finn+V&cauthor_id=33906135)[9](https://pubmed.ncbi.nlm.nih.gov/33906135/#affiliation-9), [Asociación Argentina de Estudio y Tratamiento de Fabry y otras Enfermedades Lisosomales (AADELFA), Fabry disease investigators](https://pubmed.ncbi.nlm.nih.gov/?term=Asociaci%C3%B3n+Argentina+de+Estudio+y+Tratamiento+de+Fabry+y+otras+Enfermedades+Lisosomales+%28AADELFA%29%2C+Fabry+disease+investigators%5BCorporate+Author%5D). Medicina (Buenos Aires) 2021, 81: 173-9. ISSN 1669-9106

49 "Screening for Fabry disease in Argentina's male population at all stages of chronic kidney disease", Journal of Nephrology 2022, <https://doi.org/10.1007/s40620-022-01405-x>

50 Opportunities and Challenges for Newborn Screening and Early Diagnosis of Rare Diseases in Latin America. Roberto Giugliani1, Silvia Castillo Taucher2, Sylvia Hafez3, Joao B. Oliveira4, Mariana

Rico-Restrepo5, Paula Rozenfeld6, Ignacio Zarante7, Claudia Gonzaga-Jauregui8\*. Frontiers in Genetics, 2022

13:1053559. doi: 10.3389/fgene.2022.1053559

51 Patient centered guidelines for the laboratory diagnosis of Gaucher disease type1. Dardis A, Michelakakis H, Rozenfeld P, Fumic K, Wagner J, Pavan E, Fuller M, Revel-Vilk S, Hughes D, Cox T, Aerts J. Orphanet Journal of Rare Diseases 2022 (in press).

**e) Formación de recursos humanos**

1. Directora de 1 alumno de Doctorado de la Facultad de Ciencias Exactas, UNLP
2. Directora de 1 alumno de Post-Doctorado de CONICET
3. Directora de 3 Investigadores asistentes de CONICET

**f) Premios, distinciones**

Distinción “Dr. Joaquín V. Gonzalez” a los 10 mejores promedios egresados de las Facultades Dependientes de la Universidad Nacional de La Plata, otorgada por la Municipalidad de La Plata (10 de diciembre de 1998).

Premio a la mejor Presentación de Poster. Otorgado en el 4th. International Symposium on Lysosomal Storage Diseases a los posters :

-Characteristics of Fabry Heterozygous Patients from Argentina. Rozenfeld P, Tarabuso A, Ebner R, Ramallo G,

-Characteristics of Fabry Hemizygous Patients from Argentina**.** Rozenfeld P, Tarabuso A, Ebner R, Ramallo G, ADEFA..

Premio a la mejor Presentación de Poster. Otorgado en el 5th. International Symposium on Lysosomal Storage Diseases al poster :

” Clearing of Gb3 from endothelial vessels of ocular conjunctiva in Fabry patients treated with agalsidase alfa “ Rozenfeld PA, Ebner R, Croxatto O, Fossati CA.

Primer Premio al mejor Poster de Ciencia Básica. Otorgado en el 7th. International Symposium on Lysosomal Storage Diseases al poster :

“Analysis of peripheral blood leukocyte subpopulations and cell markers from Fabry disease patients”. Rozenfeld P, Martinez P, Agriello E, de Francesco N, Aggio M, Kisinovsky I, Fossati C.

Primer Premio al mejor Poster de Ciencia Básica. Otorgado en el 8th. International Symposium on Lysosomal Storage Diseases al poster :

Proinflammatory cytokine profile from mononuclear cells of Fabry disease patients. Rozenfeld P, de Francesco N, Kisinovsky I, Fossati C. Abril de 2008

Premio a la mejor presentación en poster del area enfermedades metabólicas. Otorgado en el 29th World Congress of Internal Medicine

Poster. Anderson-Fabry disease in Argentina. PABLO NEUMANN, PABLO MARTINEZ, MARIO AGGIO , ROBERTO EBNER, RICARDO REISIN, PAULA ROZENFELD, GUILLERMO CACERES. Octubre de 2008.

Premio por el mejor trabajo en el área Básica, otorgado en el III Congreso Latinoamericano de Enfermedades Lisosomales, marzo 2010

Implementación de las determinaciones enzimáticas de iduronato-2-sulfatasa (IDS) y alfa-galactosidasa A (GLA) en vellosidades coriónicas (VC). Rozenfeld P, Ceci R, Diaz S, Masllorens F

Premio por el mejor trabajo, otorgado en el V Congreso Latinoamericano de Enfermedades Lisosomales, marzo 2013. Enhanced osteoclastogenesis by Gaucher disease patients´ mononuclear cells: implicances for bone pathology. Rozenfeld PA, Mucci JM, Cuello MF, Kisinovsky I, Larroude M, De Francesco PN, Delpino MV

Premio Bienal Faba/Fba 2014

Al investigador joven (menor a 40 años) cuya trayectoria constituya un aporte destacado en el campo de la Bioquímica Clínica.

Características: diploma y el importe de quince mil pesos ($15.000)

Premio a la Labor Científica, Tecnológica y Artística de la UNLP a Investigador Joven.

Edición 2014

Representante por la Facultad de Ciencias Exactas.

Características: diploma y el importe de cinco mil pesos ($5.000)

Premio a mejor presentación oral.

Evento: 11th C1‑inhibitor Deficiency & Angioedema Workshop

Fecha: 20 a 23 mayo de 2019

Lugar: **Hungria**

Carácter de participación: oral. Hereditary angioedema with normal C1‑inhibitor: first report of an Argentinian family with factor XII mutation

Ricardo D. Zwiener,\*,Claudio Fantini,Natalia Fili,Mónica Maroco,Paula Rozenfeld

Premio: EWGGD 2019: The best scientific oral communication

New celular models of Gaucher disease exploiting CRISPR/Cas9 Technology. Pavan E, Ormazabal M, Rozenfeld P, Dardis A

Premio: IWGGD 2022: The best scientific oral communication. MONOCYTE IN VITRO MODEL OF GAUCHER DISEASE: EVALUATION OF THE EFFECT OF THERAPIES ON INFLAMMATION AND OSTEOCLASTOGENESIS. Autors: Maximiliano Ormazabal1,2\*; Emilio Vaena1; Eleonora Pavan2; Juan Marcos Mucci1; Dania Ferino3; Adriana Cifù4; Jessica Biasizzo3, Paula Rozenfeld 1§; Andrea Dardis.